Briefs

Breast MRI Detects Cancers in Women with High-Risk Lesions

BY MELISSA WEBER

Screening with breast MRI may be particularly useful in patients with a high-risk lesion who also have a family history of breast cancer, according to a preliminary analysis of research presented at a poster session on Saturday at the San Antonio Breast Cancer Symposium. Among 83 women with a high-risk lesion... [MORE]

Herceptin More Effective If Given with Chemotherapy

BY MELISSA WEBER

Taking Herceptin (trastuzumab) with, as opposed to after, chemotherapy helped more women live longer without a recurrence, according to a phase 3 study presented Saturday at the San Antonio Breast Cancer Symposium. Investigators randomly assigned roughly 3,000... [MORE]

Blogs

DEBU TRIPATHY, MD

Updates on Treatment for HER-2 Positive Breast Cancer

In this morning's session, two updated results were presented on HER2-positive breast cancer. The first one was a trial that compared the HER2 kinase inhibitor... [MORE]

KATHY LATOUR

Advocates Everywhere at SABCS

I am always sad to leave SABCS because it's been a time to reconnect with amazing men and women who work full-time, mostly as volunteers, advocating for breast cancer and the women... [MORE]

SUSAN MCCLURE

Triple-Negative Breast Cancer Drug One Step Closer to Approval

On Friday, sanofi-aventis announced that the FDA has granted fast track approval to their investigational PARP1 inhibitor, BSI-201, and that accruals for their phase 3... [MORE]

BEV PARKER

Advocates Question the Experts

For advocates, a significant highlight of the symposium is always the evening "Hot Topics" sessions, now in their 12th year. Hot Topics is sponsored by the Alamo Breast Cancer Foundation, which this year... [MORE]

Message Board

Are you HER2-positive? Do you use Herceptin? Share your experience on the CURE Message Board.

PROFILE:

Advocating for the African American Community

BY KATHY LATOUR

Vernal Branch says she hopes the data on black women, who are HER2-positive and HER2-negative and are having a worse outcome when treated... [MORE]

Become a fan of CURE on Facebook.

Follow CURE on Twitter.

Send feedback to editor@curetoday.com.

Sign up for our e-mail newsletters, which you can now personalize by tumor type, survivorship, or caregiver status.

This e-mail was sent to you because you have provided your e-mail address to CURE. CURE is committed to protecting your privacy and no information about our subscribers is sold to any outside party.

Please add enews@curetoday.com to your address book or safe sender list to ensure this e-mail is delivered to your inbox.

2009 CURE Media Group. All rights reserved. Terms of Use

Disclaimer: CURE does not provide medical, diagnostic, or treatment advice.